A Double Blind (3rd Party Open), Randomized, Placebo Controlled, Parallel Group, Dose Escalation Study To Investigate The Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-04531083 In Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 18 Dec 2009
At a glance
- Drugs PF 4531083 (Primary)
- Indications Pain
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 18 Dec 2009 Actual end date (1 Dec 2009) added as reported by ClinicalTrials.gov record.
- 18 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 20 Oct 2009 New trial record